JP2017520583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520583A5 JP2017520583A5 JP2016575950A JP2016575950A JP2017520583A5 JP 2017520583 A5 JP2017520583 A5 JP 2017520583A5 JP 2016575950 A JP2016575950 A JP 2016575950A JP 2016575950 A JP2016575950 A JP 2016575950A JP 2017520583 A5 JP2017520583 A5 JP 2017520583A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- asc
- sepsis
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002536 stromal cell Anatomy 0.000 claims description 16
- 206010040047 Sepsis Diseases 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 7
- -1 CD49A Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 2
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 102100037241 Endoglin Human genes 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102000011782 Keratins Human genes 0.000 claims description 2
- 108010076876 Keratins Proteins 0.000 claims description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 102100038021 Steryl-sulfatase Human genes 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 2
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14175095.0 | 2014-06-30 | ||
| EP14175095 | 2014-06-30 | ||
| PCT/IB2015/054923 WO2016001846A1 (en) | 2014-06-30 | 2015-06-30 | Mesenchymal stromal cells for treating sepsis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520583A JP2017520583A (ja) | 2017-07-27 |
| JP2017520583A5 true JP2017520583A5 (enExample) | 2018-08-09 |
| JP6722599B2 JP6722599B2 (ja) | 2020-07-15 |
Family
ID=51033023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575950A Active JP6722599B2 (ja) | 2014-06-30 | 2015-06-30 | 全身性炎症反応症候群の治療のための間葉系間質細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170151284A1 (enExample) |
| EP (1) | EP3160481B1 (enExample) |
| JP (1) | JP6722599B2 (enExample) |
| KR (1) | KR102213527B1 (enExample) |
| CN (1) | CN106573017B (enExample) |
| AU (1) | AU2015283662B2 (enExample) |
| BR (1) | BR112016030758B8 (enExample) |
| CA (1) | CA2953884C (enExample) |
| IL (1) | IL249814B (enExample) |
| MX (1) | MX381544B (enExample) |
| NZ (1) | NZ727950A (enExample) |
| RU (1) | RU2715866C2 (enExample) |
| SG (1) | SG11201610844PA (enExample) |
| WO (1) | WO2016001846A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11518982B2 (en) * | 2015-12-01 | 2022-12-06 | Adiposeeds, Inc. | Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue |
| WO2017156235A1 (en) * | 2016-03-09 | 2017-09-14 | Emory University | Methods of preserving mesenchymal stem cells |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| EP4091618A1 (fr) | 2017-02-28 | 2022-11-23 | Université de Lorraine | Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis |
| WO2019084010A1 (en) | 2017-10-26 | 2019-05-02 | Emory University | MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE |
| AU2019283518B2 (en) * | 2018-06-05 | 2025-09-11 | Medipost Co., Ltd. | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
| EP3874029B1 (en) * | 2018-10-29 | 2023-08-30 | Ottawa Hospital Research Institute | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof |
| EP4098267A4 (en) * | 2020-01-30 | 2024-03-06 | JCR Pharmaceuticals Co., Ltd. | MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP |
| EP4351721A4 (en) * | 2021-05-13 | 2025-04-30 | Primegen US, Inc. | Methods and compositions for the treatment of liver diseases |
| CN113398150A (zh) * | 2021-06-18 | 2021-09-17 | 卡替(上海)生物技术有限公司 | 牙髓间充质干细胞在脓毒症治疗中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69317439T2 (de) | 1992-12-02 | 1998-07-02 | Shell Int Research | Azoxycyanbenzol-Derivate |
| US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5705308A (en) | 1996-09-30 | 1998-01-06 | Eastman Kodak Company | Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element |
| US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| EP2298863B1 (en) * | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| CA2623353C (en) | 2005-09-23 | 2017-02-21 | Cellerix, S.L. | Cell populations having immunoregulatory activity, method for isolation and uses |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| US9901600B2 (en) * | 2011-03-11 | 2018-02-27 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
| JP2014016782A (ja) * | 2012-07-09 | 2014-01-30 | Toshiba Corp | 情報処理装置およびプログラム |
| US20140134140A1 (en) * | 2012-11-09 | 2014-05-15 | Case Western Reserve University | Mesenchymal stem cell compositions for the treatment of microbial infections |
-
2015
- 2015-06-30 NZ NZ727950A patent/NZ727950A/en unknown
- 2015-06-30 AU AU2015283662A patent/AU2015283662B2/en active Active
- 2015-06-30 EP EP15742102.5A patent/EP3160481B1/en active Active
- 2015-06-30 RU RU2016151738A patent/RU2715866C2/ru active
- 2015-06-30 CN CN201580042833.7A patent/CN106573017B/zh active Active
- 2015-06-30 BR BR112016030758A patent/BR112016030758B8/pt active IP Right Grant
- 2015-06-30 KR KR1020177002380A patent/KR102213527B1/ko active Active
- 2015-06-30 MX MX2017000142A patent/MX381544B/es unknown
- 2015-06-30 JP JP2016575950A patent/JP6722599B2/ja active Active
- 2015-06-30 WO PCT/IB2015/054923 patent/WO2016001846A1/en not_active Ceased
- 2015-06-30 US US15/323,373 patent/US20170151284A1/en not_active Abandoned
- 2015-06-30 CA CA2953884A patent/CA2953884C/en active Active
- 2015-06-30 SG SG11201610844PA patent/SG11201610844PA/en unknown
-
2016
- 2016-12-28 IL IL249814A patent/IL249814B/en active IP Right Grant
-
2020
- 2020-08-14 US US16/994,379 patent/US20200376038A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | The secretion profile of mesenchymal stem cells and potential applications in treating human diseases | |
| JP2016523285A5 (enExample) | ||
| RU2010153362A (ru) | Способы лечения воспалительных заболеваний ободочной кишки | |
| Malgieri et al. | Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art | |
| RU2016151738A (ru) | Мезенхимальные стромальные клетки для лечения синдрома системной воспалительной реакции | |
| Ejtehadifar et al. | The effect of hypoxia on mesenchymal stem cell biology | |
| Li et al. | Bone‐marrow‐derived mesenchymal stem cells for organ repair | |
| Zhao et al. | The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation | |
| JP2014509319A5 (enExample) | ||
| Guadix et al. | Characteristics, applications and prospects of mesenchymal stem cells in cell therapy | |
| HRP20120887T4 (hr) | Adherentne stanice iz masnog i tkiva posteljice i njihova upotreba u terapiji | |
| JP2014000094A5 (ja) | 臍帯由来細胞を用いた局部的または散在的脳外傷の改善 | |
| MY202675A (en) | A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium | |
| Elnakish et al. | Mesenchymal stem cells for cardiac regeneration: translation to bedside reality | |
| JP2014208682A5 (enExample) | ||
| Liang et al. | Mesenchymal stem cell therapy for patients with ischemic heart failure-past, present, and future | |
| El-Haibi et al. | Mesenchymal stem cells in the pathogenesis and therapy of breast cancer | |
| RU2013141914A (ru) | Лечение амиотрофического бокового склероза с использованием полученных из пуповины клеток | |
| JP2017520582A5 (enExample) | ||
| JP2019508455A5 (enExample) | ||
| Zhang et al. | Effects of Rehmannia glutinosa oligosaccharide on human adipose-derived mesenchymal stem cells in vitro | |
| Götherström | Human foetal mesenchymal stem cells | |
| WO2012033352A3 (ko) | 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법 | |
| Pershina et al. | MSCs of pulmonary in Bleomycin-induced Pulmonary Fibrosis | |
| US20240366737A1 (en) | Compositions for inhibiting teratoma formation and growth comprising timp-1 and timp-2 as effective components |